An investigation into the safety, tolerability, and efficacy of high dose rivastigmine treatment in Alzheimer's disease

被引：0
|
作者：
Shua-Haim, JR [1 ]
Pass, MD [1 ]
Patel, S [1 ]
Lee, P [1 ]
Patel, P [1 ]
机构：
[1] Jersey Shore Univ Med Ctr, Neptune, NJ USA
来源：
NEUROBIOLOGY OF AGING | 2004年 / 25卷
关键词：
D O I：
10.1016/S0197-4580(04)80659-6
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
引用
收藏
页码：S196 / S196
页数：1
相关论文
共 50 条
  • [31] An open randomized comparative study of clinical efficacy and safety of huperzine A and rivastigmine in treatment of mild to moderate Alzheimer's disease
    Wu, Y. C.
    Zhao, Y. B.
    Xie, Y. Y.
    Wang, W. Z.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 : 198 - 199
  • [32] Response to comments on Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil
    Auriacombe, S
    Pere, JJ
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2002, 18 (06) : IV - VI
  • [33] Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer's Disease: A Systematic Review and Meta-Analysis
    Tan, Chen-Chen
    Yu, Jin-Tai
    Wang, Hui-Fu
    Tan, Meng-Shan
    Meng, Xiang-Fei
    Wang, Chong
    Jiang, Teng
    Zhu, Xi-Chen
    Tan, Lan
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2014, 41 (02) : 615 - 631
  • [34] The efficacy and safety of memantine for the treatment of Alzheimer's disease
    Matsunaga, Shinji
    Kishi, Taro
    Nomura, Ikuo
    Sakuma, Kenji
    Okuya, Makoto
    Ikuta, Toshikazu
    Iwata, Nakao
    [J]. EXPERT OPINION ON DRUG SAFETY, 2018, 17 (10) : 1053 - 1061
  • [35] Safety/Tolerability and Efficacy of Rivastigmine in Taiwanese Patients with Alzheimer’s DiseaseA Prospective Post-Marketing Surveillance Study
    Pai-Yi Chiu
    Dao-En Dai
    Hai-Pei Hsu
    Chao Lee
    Juei-Jueng Lin
    Hung-Chou Kuo
    Ying-Chih Huang
    Yung-Chang Liu
    Ching-Piao Tsai
    [J]. Clinical Drug Investigation, 2009, 29 : 729 - 738
  • [36] Donepezil: Tolerability and safety in Alzheimer's disease
    Pratt, RD
    Perdomo, CA
    Surick, IW
    Ieni, JR
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2002, 56 (09) : 710 - 717
  • [37] A head to head study of donepezil, rivastigmine, and galantamine for the treatment of Alzheimer's disease: Safety, tolerability, clinical and caregiver impressions after 9 months of treatment
    Shua-Haim, JR
    Pass, MD
    Patel, S
    Patel, S
    Lee, P
    Patel, P
    Smith, J
    [J]. NEUROBIOLOGY OF AGING, 2004, 25 : S208 - S208
  • [38] Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease
    Burns, A
    Spiegel, R
    Quarg, P
    [J]. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2004, 19 (03) : 243 - 249
  • [39] Efficacy of rivastigmine tartrate, transdermal system, in Alzheimer's disease
    Nieto, Rachel A.
    Deardorff, William James
    Grossberg, George T.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (06) : 861 - 870
  • [40] Efficacy of rivastigmine on loss of appetite in patients with Alzheimer's disease
    Tsuno, N.
    Mori, T.
    Nakamura, Y.
    [J]. EUROPEAN PSYCHIATRY, 2017, 41 : S176 - S177
12345